A cancer drug is being touted online as a way to grow taller – what you need to know
Leona Octavii/Shutterstock.com A cancer drug linked to rapid growth spurts in children has caught the attention of teenagers looking to gain an extra few inches in height. Erdafitinib, a medicine designed to treat advanced cancer, has been linked to extraordinary growth spurts in children receiving treatment for brain tumours. Reports of these effects have fuelled interest among people seeking to maximise their height – so-called “heightmaxxing”, though it’s unclear how many are actually taking…
Places named in this report: Vienna
Exact coordinates
vienna: 48.210, 16.370
Read it at The Conversation See this on the map
What might happen next? AI-generated
These scenarios are written by an AI language model from the headline and summary above. They are not predictions from the newsroom, and they are not evidence of anything. Every one is given a deadline and checked against later coverage, and the score is published on the ledger — including the ones that miss.
-
Awaiting deadline 40% Platform crackdown and health warnings
TikTok and other platforms expand their bans, removing more accounts promoting erdafitinib for height and adding prominent safety labels linking the drug to vision loss and skeletal deformity. Public health agencies issue joint statements discouraging use, and the trend fades from mainstream feeds as the most virulent posts are taken down.
Watch for: TikTok issues a blog post announcing expanded removal of 'heightmaxxing' and erdafitinib-related accounts · A national health authority posts an advisory warning teenagers against using erdafitinib for height · News headline reports 'Tiktok cracks down on TikTok height-drug trend'
-
Awaiting deadline 30% High-profile harm cases surface
Emergency departments or medical journals report adolescents who bought erdafitinib online and suffered adverse effects such as vision problems, elevated phosphate, or skeletal pain. These cases draw mainstream news coverage, shifting the online narrative away from height gains toward documented danger and reinforcing expert warnings.
Watch for: A hospital or medical journal reports a teenager hospitalized after taking erdafitinib for height · News headline reads 'Doctors warn of vision loss in teens buying cancer drug online' · Regulatory agency announces an investigation into online sellers of erdafitinib
-
Awaiting deadline 20% Trend normalizes and lingers
Without major platform action or reported harm, the heightmaxxing discussion continues across smaller communities and alternative platforms, with users sharing anecdotes and sourcing advice. Coverage remains limited, the drug stays accessible online, and the topic persists as a niche but ongoing online culture phenomenon.
Watch for: Coverage shows the heightmaxxing discussion continuing across multiple platforms with no new restrictions · News reports describe continued online sourcing of erdafitinib outside traditional pharmacy channels · No major regulatory or platform enforcement action is announced
-
Awaiting deadline 10% Pharmaceutical and clinical response
The drug's manufacturer or researchers publicly address the off-label use, either by tightening distribution controls or by announcing interest in studying the FGFR3 pathway for legitimate growth disorders. Legitimate medical attention redirects the story from internet curiosity toward a serious scientific and regulatory discussion.
Watch for: The drug's manufacturer issues a statement addressing off-label height use · Researchers announce a clinical study or trial targeting the FGFR3 pathway for growth disorders · A regulatory body restricts or flags erdafitinib distribution following the online trend
Generated by tiel-coder-35b-a3b-ud-q4_k_xl
on 2026-11-16. Checked against later coverage after 2026-11-23.
See how these forecasts score.
ForecastGeo shows the headline and summary published by the newsroom and places the story on a map. The full article lives at the source.